AKCA - Akcea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.85
-1.59 (-5.40%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close29.44
Open29.31
Bid18.00 x 900
Ask31.00 x 800
Day's Range27.70 - 29.90
52 Week Range17.74 - 40.75
Volume212,323
Avg. Volume248,255
Market Cap2.491B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.25
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that data from the NEURO-TTR open-label extension study and the clinical impact of TEGSEDI on patients living with hereditary transthyretin amyloidosis (hATTR) will be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC) in New Orleans, March 16-18, 2019.

  • Why Akcea Therapeutics, Inc. (NASDAQ:AKCA) Is A Financially Healthy Company
    Simply Wall St.15 days ago

    Why Akcea Therapeutics, Inc. (NASDAQ:AKCA) Is A Financially Healthy Company

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Akcea Therapeutics, Inc. (NASDAQ:AKCA), with a market cap of US$2.7b, are often out of theRead More...

  • GlobeNewswire17 days ago

    Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs
    Motley Fool19 days ago

    Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs

    The biotech turned an operating profit in the fourth quarter thanks to revenue from partners.

  • Reuters22 days ago

    EU committee approves Akcea-Ionis drug for rare genetic disease

    An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood. The nod from EMA's Committee for Medicinal Products for Human Use is a shot in the arm for the companies after their shares plunged in August when the U.S. Food and Drug Administration declined to approve the drug, Waylivra. Waylivra is designed to treat familial chylomicronemia syndrome, a rare genetic disorder that can cause a potential fatal inflammation of the pancreas.

  • GlobeNewswire22 days ago

    Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) who are at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. Click here to read the EMA’s press release. The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union for the adoption of a decision on an EU-wide marketing authorization.

  • GlobeNewswire23 days ago

    Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease. “For most people living with a rare disease, management of their condition is often a significant challenge and can impact many aspects of their daily lives including the ability to perform at work or school or take care of their families,” said Paula Soteropoulos, chief executive officer at Akcea.

  • Here's Why Ionis Pharmaceuticals Jumped Higher Today
    Motley Fool24 days ago

    Here's Why Ionis Pharmaceuticals Jumped Higher Today

    Fourth-quarter earnings exceed expectations.

  • Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool24 days ago

    Akcea Therapeutics, Inc. (AKCA) Q4 2018 Earnings Conference Call Transcript

    AKCA earnings call for the period ending December 31, 2018.

  • GlobeNewswire25 days ago

    Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018

    TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2.

  • ACCESSWIRE25 days ago

    Akcea Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Akcea Therapeutics, Inc. (NASDAQ: AKCA ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 ...

  • GlobeNewswire26 days ago

    AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.

  • GlobeNewswirelast month

    Akcea Therapeutics to Present at Upcoming Investor Conferences

    Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. In this press release, unless the context requires otherwise, “Ionis”, “Akcea,” “Company,” “Companies” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Yelp, Jabil, SBA Communications, comScore, AVX, and Akcea Therapeutics — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 26th at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2018 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks2 months ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily2 months ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
    Investor's Business Daily4 months ago

    Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis

    Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.

  • GlobeNewswire4 months ago

    Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the NEURO-TTR open-label extension study and TEGSEDI’s impact on the lives of patients living with polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR) at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, California, December 1-4, 2018. In addition to the oral presentation, a poster on the benefit of TEGSEDI to patients from the NEURO-TTR study will be presented.

  • GlobeNewswire5 months ago

    Akcea Reports Financial Results and Highlights for Third Quarter 2018

    TEGSEDITM (inotersen) Approved in United States, European Union & Canada        $320 million to fund the company through key milestones Conference Call.

  • Benzinga5 months ago

    Akcea Therapeutics Q3 Earnings Preview

    On Monday, Nov. 5, Akcea Therapeutics (NASDAQ: AKCA ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Analysts ...